Boston Scientific, which presented the results over the weekend at the Heart Rhythm Society meeting, expects to receive FDA approval for the system in 2025.
Boston Scientific’s cardiac rhythm system hit pivotal trial goals Read More »
Las apuestas deportivas, se han convertido hoy día en una actividad muy popular; ya sea, como práctica de entretenimiento, pero a la vez, una manera de obtener ganancias monetarias. Para ello, es importante el desarrollo de estrategias que permitan al jugador un mejo …
More than 50 providers are asking the federal government to publicly state that UnitedHealth should handle data breach reporting stemming from the cyberattack on its subsidiary.
Providers urge HHS to clarify Change data breach reporting requirements Read More »
According to latest study, the U.S. mRNA therapeutics market size was worth around USD 5.10 billion in 2023 and is predicted to grow around USD 12.18 billion by 2033 with a compound annual growth rate (CAGR) of roughly 9.1% between 2024 and 2033.
U.S. mRNA Therapeutics Market Size to Worth USD 12.18 Bn by 2033 Read More »
La sostenibilidad es un tema cada vez más relevante en el ámbito de la tecnología. A medida que las empresas se vuelven más conscientes del impacto ambiental de sus operaciones, buscan maneras de ser más sostenibles. La reutilización de tecnolog&ia …
Cómo la tecnología reutilizada contribuye a la sostenibilidad ambiental Read More »
Aktis Oncology, a biotechnology company discovering and developing novel targeted radiopharmaceuticals to treat a broad range of solid tumors, announced a multi-target discovery collaboration agreement with Eli Lilly and Company to generate anticancer radiopharmaceuticals using Aktis Oncology’s novel miniprotein technology platform.
Bristol Myers Squibb announced that the FDA has reassigned the previously announced PDUFA goal date of the BLA for the subcutaneous formulation of Opdivo® co-formulated with Halozyme’s proprietary recombinant human hyaluronidase across all previously approved adult, solid tumor Opdivo indications as monotherapy, monotherapy maintenance following completion of Opdivo plus Yervoy combination therapy, or in combination
Cantargia Cantargia announced its interim report for the first quarter of 2024.
Cantargia Publishes Interim Report for the First Quarter of 2024 Read More »
Dragonfly Therapeutics, Inc., a clinical stage biotechnology company developing novel immunotherapies, announced that it has entered into a clinical collaboration with Merck, to evaluate DF9001, Dragonfly’s EGFR immune engager, in combination with Merck’s anti-PD-1 therapy, KEYTRUDA®, in patients with advanced solid tumors expressing EGFR.
La ciencia ficción prácticamente se ha vuelto realidad y la IA es solo una prueba de ello. Cada vez son más las personas que utilizan esta novedosa herramienta, por lo que tampoco es extraño que las empresas aprovechen sus beneficios. En especial porque la tecnologí …
7 ejemplos del uso de la IA en el día a día de muchas empresas Read More »
